PROTHENA CORP PUBLIC LTD CO
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Prothena is a clinical-stage biotechnology company focused on developing therapies targeting protein misfolding, primarily for neurological and rare diseases such as amyloidosis and Parkinson's disease. It advances these drug candidates through research and clinical trials, often in partnership with larger pharmaceutical companies.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| SCULLY WILLIAM P10% Owner | Buy | $890K | 103,500at $8.60 | Sep 28, 2026 |
| SCULLY WILLIAM P10% Owner | Buy | $439K | 50,000at $8.79 | Aug 20, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable PRTA activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.